Peer Review History

Original SubmissionJuly 17, 2023
Decision Letter - Robert Jeenchen Chen, Editor

PONE-D-23-21699Severe COVID-19 Infection: An Institutional Review and Literature ReviewPLOS ONE

Dear Dr. Akpoviroro,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please revise.

Please submit your revised manuscript by Nov 16 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Robert Jeenchen Chen, MD, MPH

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. 

4. Please include your tables as part of your main manuscript and remove the individual files. Please note that supplementary tables (should remain/ be uploaded) as separate "supporting information" files. 

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Congratulations on a work well done.

Four years after the pandemic, most of the data listed is already known and published everywhere regarding outcomes I different demographics.

However, the way the results were listed and discussed is very appealing to read. Hence, my suggestion to change the way the paper was written and focus on reformatting the manuscript

Reviewer #2: This is an interesting paper by Akpoviroro et al. describing patients with severe COVID-19.

Some comments for the authors' consideration:

1) The study would greatly benefit from a flow chart figure that outlines eligibility and inclusion.

2) The statistical analysis is more descriptive rather than forming associations. Please revise all indications that associations were found. Statistical methods used only describe significant differences between groups.

3) While the title suggests that it is also a literature review, there is no formal literature search conducted or included in the methods

4) The discussion is rather long, and perhaps should be a separate paper itself.

5) Please justify the sample size or include a sample size calculation.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Mahmoud Elfiky

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

1) Thank you for your feedback. We have incorporated a flow chart outlining the inclusion criteria and outcome groups into the manuscript as a figure.

2) Thank you for your thoughtful comment regarding the use of descriptive statistics in our study. We employed the Chi-squared test, also known as the chi-square test for association or contingency, to analyze our data. The primary purpose of the chi-square test in statistical analyses is to demonstrate associations between categorical data. It is important to note that association does not imply causation, and we have taken great care not to suggest a cause-and-effect relationship in our findings. We believe that the term "association" accurately characterizes the outcomes based on the statistical tests conducted in our study. Nevertheless, we genuinely value your input and in response, we have taken the time to clarify and explicitly state that any associations found in our study results are purely statistical in nature. This precautionary measure is to prevent any potential misunderstandings among our readers and to ensure that our work is accurately represented. If we have erroneously indicated a cause-and-effect relationship in any of our study results, please definitely indicate where these errors are, and we will enthusiastically make the appropriate adjustments. Once again, thank you for your insightful comment; we truly appreciate your engagement with our work and helping to enhance the clarity of our research.

3) Thank you for bringing this to our attention. We acknowledge that we did not explicitly state in the title or elsewhere in the manuscript that a systematic review was conducted. While we conducted a thorough search for existing literature, it was not done in line with a conventional systematic review process, which was not the primary focus of our manuscript. To ensure transparency and avoid any confusion, we have revised the manuscript's title, replacing the term "review" with "overview." We trust that this modification better communicates the nature of the discussion in our manuscript.

4) Thank you for your feedback on the manuscript length. We appreciate your perspective on this matter and understand your concerns. We have carefully considered your comments alongside our objectives and have decided to maintain the current length of the manuscript. We believe this length is necessary to comprehensively cover the topic and provide valuable insights to our readers. Your input is valuable, and we hope you understand our reasoning. If you have any further suggestions or specific areas you feel could be condensed, we would be more than happy to hear them.

5) A post-hoc statistical power analysis was calculated using G*Power Calculator v3.1.9.7 provided by Heinrich Heine University Düsseldorf. This was used to determine the likelihood of detection given our sample size. Of the statistically significant variables, it was found that there was a >80% statistical power on 20/28 tests, or 71.4% of significant tests. The eight tests that were significant but not >80% power all had >60% power with the exception of average bilirubin (mg/dL) and ethnicity. These lower powers are most likely due to the small sample size and the disparity of sizes between groups. A supplemental file has been attached detailing these findings.

Decision Letter - Robert Jeenchen Chen, Editor

PONE-D-23-21699R1Severe COVID-19 Infection: An Institutional Review and Literature OverviewPLOS ONE

Dear Dr. Akpoviroro,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please revise.

Please submit your revised manuscript by Jan 15 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Robert Jeenchen Chen, MD, MPH

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #3: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Congratulations on the work and the paper. It seems everything has been addressed to the slightest detail

Reviewer #3: Congratulations to address COVID-19 risk factors and the importance of being vaccinated.

Your study is well written but there is too much information. Despite being a observational study ,the authors conduct a detailed review of all the variables shown in the results section, giving the impression for the reader that we are reading a narrative review. It is important to adequate the lenght of the writing to not become tiring to the reader. The discussion section should point out the main topics to guide the reader through the authors point of view to support their findings.

I suggest to reduce the discussion section as the core of the paper is a observational study and their findings.

I suggest put table 6 ( medication ) in supplemental matherial and point out in the results and discussion section the most relevant points in this section.

I suggest put the limitations and strenghts section before the conclusion .

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Mahmoud Elfiky

Reviewer #3: Yes: Marcelo Rodrigues Bacci

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 2

December 23, 2023,

Editor in Chief

PLOS ONE

Subject: Submission of revised manuscript (PONE-D-23-21699)

Dear Dr. Chen,

We are pleased to re-submit a revised version of our manuscript titled, “Severe COVID-19 Infection: An Institutional Review and Literature Overview”.

Thank you for the opportunity to revise and resubmit this manuscript. According to the deadline provided, I am submitting this revision before 01/15/2024. We would like to thank you and the reviewers for the time taken to review our manuscript, and the insightful recommendations that were provided. We have incorporated the suggested changes into the manuscript as much as possible. We look forward to working with you and the reviewers to move this manuscript closer to publication in PLOS ONE.

We have tracked any changes made to the manuscript document. We have specifically responded to each reviewer’s comments below. We have numbered each reviewer’s comment, followed with a response detailing how we have addressed the comment.

Review Comments to the Author

Reviewer #1: Congratulations on the work and the paper. It seems everything has been addressed to the slightest detail

Response to review #1

Thank you for your thoughtful review. We appreciate your time and effort in evaluating our work. We are delighted to hear that you found our paper comprehensive and that we have successfully addressed the details to your satisfaction.

Reviewer #3: Congratulations to address COVID-19 risk factors and the importance of being vaccinated.

Your study is well written but there is too much information. Despite being a observational study ,the authors conduct a detailed review of all the variables shown in the results section, giving the impression for the reader that we are reading a narrative review. It is important to adequate the lenght of the writing to not become tiring to the reader. The discussion section should point out the main topics to guide the reader through the authors point of view to support their findings. I suggest to reduce the discussion section as the core of the paper is a observational study and their findings. I suggest put table 6 ( medication ) in supplemental matherial and point out in the results and discussion section the most relevant points in this section. I suggest put the limitations and trengths section before the conclusion .

Response to reviewer #3

Thank you for your thoughtful comments. We appreciate your recognition of the detailed overview that all the authors have carefully worked together to collate.

Our aim is to present an unbiased portrayal of our findings, including both supportive and opposing studies. We have also provided possible explanations for discrepancies and believe our comprehensive approach offers valuable insights in a neutral manner. We value your input and the time dedicated to enhancing our paper. We have significantly condensed the discussion by eliminating less relevant findings, removing over two thousand words and 28 references. Additionally, we have placed Table 6 in the supplemental material file, referencing it appropriately in the main text, and reorganized the limitation and conclusion sections as suggested. We hope that these changes improve the manuscript’s readability while maintaining a thorough coverage of this topic.

Sincerely,

Ogheneyoma Akpoviroro, MD

Geisinger Northeast/Geisinger Wyoming Valley Medical Center

1000 East Mountain Boulevard

Wilkes Barre, Pennsylvania 18711

United States

570-808-3746

oakpoviroro@geisinger.edu

o.akpoviroro@gmail.com

Attachments
Attachment
Submitted filename: Response to reviewers plos one 12.23.23.docx
Decision Letter - Robert Jeenchen Chen, Editor

Severe COVID-19 Infection: An Institutional Review and Literature Overview

PONE-D-23-21699R2

Dear Dr. Akpoviroro,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Robert Jeenchen Chen, MD, MPH

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #4: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #4: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #4: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #4: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #4: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Excellent manuscript and all comments have been addressed. Thank you for addressing them all and responding to the reviewers

Reviewer #4: It seems that all the recommendations made by the reviewers were followed in a detailed and careful manner. Congratulations on the work.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Mahmoud Elfiky

Reviewer #4: No

**********

Formally Accepted
Acceptance Letter - Robert Jeenchen Chen, Editor

PONE-D-23-21699R2

PLOS ONE

Dear Dr. Akpoviroro,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Robert Jeenchen Chen

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .